Australia markets closed

Regeneus Ltd (RGS.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.04300.0000 (0.00%)
At close: 11:45AM AEDT

Regeneus Ltd

2 Paddington Street
Paddington, NSW 2021
1300 995 098

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Karolis RosickasChief Exec. Officer526.15kN/AN/A
Prof. Graham Vesey Ph.D.Chief Scientific Officer & Exec. Director120.87kN/A1965
Dr. Charlotte Morgan Ph.D.Head of R&DN/AN/AN/A
Ling Leung HangCompany Sec.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. Its lead platform technology includes Progenza, a multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was incorporated in 2007 and is headquartered in Paddington, Australia.

Corporate governance

Regeneus Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.